Author Interviews, Neurology, Pain Research / 25.09.2018
Need For Better Treatments For Chronic Nerve Pain After Trauma Remains Serious Problem
MedicalResearch.com Interview with:
[caption id="attachment_44791" align="alignleft" width="172"]
Dr. Markman[/caption]
John Douglas Markman, M.D.
Director, Translational Pain Research Program
Department of Neurosurgery
Professor
University of Rochester School of Medicine and Dentistry
MedicalResearch.com: What is the background for this study?
Response: Peripheral nerve injury after trauma and surgery is a leading cause of chronic pain and disability. These pain syndromes are often considered to have an underlying neuropathic mechanism because there is altered sensory processing (e.g., numbness, allodynia) at the site of trauma or surgical incision that localizes to the anatomic distribution of a peripheral nerve. A previous eight-week randomized clinical trial demonstrated efficacy for pregabalin in patients with chronic post-traumatic or -surgical pain.(10) The longer duration of treatment of this study was designed to meet the regulatory standard for a chronic pain indication in the US, 12 weeks of treatment at maintenance or fixed dosing.
Dr. Markman[/caption]
John Douglas Markman, M.D.
Director, Translational Pain Research Program
Department of Neurosurgery
Professor
University of Rochester School of Medicine and Dentistry
MedicalResearch.com: What is the background for this study?
Response: Peripheral nerve injury after trauma and surgery is a leading cause of chronic pain and disability. These pain syndromes are often considered to have an underlying neuropathic mechanism because there is altered sensory processing (e.g., numbness, allodynia) at the site of trauma or surgical incision that localizes to the anatomic distribution of a peripheral nerve. A previous eight-week randomized clinical trial demonstrated efficacy for pregabalin in patients with chronic post-traumatic or -surgical pain.(10) The longer duration of treatment of this study was designed to meet the regulatory standard for a chronic pain indication in the US, 12 weeks of treatment at maintenance or fixed dosing.
